EC approves Keytruda joint Alimta first-line treatment of metastatic non-squamous non-small cell lung cancer adult patients

recently, the cancer immunotherapy giant Merck and Co announced that the European Commission (EC) has approved the PD-1 tumor immunotherapy Keytruda (pembrolizumab, Pablo bead monoantigen) combined Alimta (Chinese brand name: Libita, Generic name: pemelic and platinum chemotherapy (cisplatin or caplatinum), first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) adult patients without EGFR or ALK-positive mutations, regardless of PD-L1 expression statusthis approval, making Keytruda and Pemexaaaaaa a platinum-containing chemotherapy protocol the first in Europe to be approved for first-line treatment of metastasis edgy non-scaly NSCLC for chemotherapy-PD-1 immunotherapy combinationthis approval is based on total lifetime (OS) and no progressive rebirth (PFS) data for Phase III clinical studiesThe study showed a significant improvement in THE OS and PFS os (OS: HR s.49,95% CI) in the Keytruda Treatment Group (Keytruda and Pemese and Platinum) compared to the placebo group (placebo-pemere-and-platinum) : 0.38-0.64, p 0.00001; PFS:HR: 0.52, 95%CI: 0.43-0.64, p 0.00001)the approval applies to all 28 EU member states, as well as Iceland, Liechtenstein and NorwayKeytruda recommends an intravenous infusion of 200 mg every 3 weeks until the disease progresses or is unacceptable toxicityIn Europe, Keytruda has also been approved: (1) as a single-drug therapy for patients with high lysicle PD-L1 (TPS -50%) and no EGFR or ALK-positive tumor mutations in patients with metastatic scaly or non-scaly NSCLC (1) Based on the KEYNOTE-024 study) ;(2) as a single-drug therapy for localized advanced or metastatic NSCLC patients (based on the KEYNOTE-010 study) who have previously received at least one chemotherapy regimen and whose tumor expression PD-L1 (TPS is 1%)this approval, making Keytruda the first and only anti-PD-1 therapy approved for advanced melanoma in the Chinese market, and the second anti-PD-1 therapy approved in the Chinese market after Perilife's Squibb Opdivo, which was approved in mid-June this yearApproved for second-line treatment of non-small cell lung cancer (NSCLC), specifically EGFR-negative, ALK-negative, advanced or intolerant localized advanced or metastatic non-small cell lung cancer (NSCLC) adult patients after receiving platinum-containing chemotherapy